Healthcare · Biotechnology · NASDAQ
| Market cap | $21.66B |
|---|---|
| Trailing P/E | 23.8 |
| FCF yield | 5.1% |
| Revenue growth (YoY) | +19.2% |
| EPS growth (YoY) | -1.7% |
| FCF/share growth (YoY) | +7.8% |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
Genmab A/S trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Alan Armstrong | Senate | Buy | $1,001 - $15,000 | Jul 21, 2026 |
| Alan Armstrong | Senate | Buy | $1,001 - $15,000 | Jul 21, 2026 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Feb 10, 2025 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Jan 14, 2025 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Aug 15, 2024 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Jul 9, 2024 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Nov 11, 2023 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Oct 15, 2023 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Aug 21, 2023 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Aug 21, 2023 |
| Daniel Goldman | House | Sell | $50,001 - $100,000 | Aug 13, 2023 |
| Thomas R Carper | Senate | Buy | $1,001 - $15,000 | — |